1. Home
  2. ZVIA vs ACOG Comparison

ZVIA vs ACOG Comparison

Compare ZVIA & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zevia PBC

ZVIA

Zevia PBC

HOLD

Current Price

$1.16

Market Cap

96.4M

ML Signal

HOLD

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$6.88

Market Cap

110.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZVIA
ACOG
Founded
2007
2000
Country
United States
Canada
Employees
N/A
57
Industry
Beverages (Production/Distribution)
Sector
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
96.4M
110.4M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
ZVIA
ACOG
Price
$1.16
$6.88
Analyst Decision
Buy
Strong Buy
Analyst Count
4
1
Target Price
$4.93
$18.00
AVG Volume (30 Days)
513.9K
59.4K
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
55.88
N/A
EPS
N/A
N/A
Revenue
$161,259,000.00
N/A
Revenue This Year
$8.33
$146.05
Revenue Next Year
$6.84
$127.74
P/E Ratio
N/A
N/A
Revenue Growth
4.01
N/A
52 Week Low
$1.11
$3.97
52 Week High
$3.66
$10.88

Technical Indicators

Market Signals
Indicator
ZVIA
ACOG
Relative Strength Index (RSI) 35.33 70.66
Support Level $1.12 $6.46
Resistance Level $2.76 $7.83
Average True Range (ATR) 0.07 0.52
MACD 0.02 0.11
Stochastic Oscillator 25.00 89.91

Price Performance

Historical Comparison
ZVIA
ACOG

About ZVIA Zevia PBC

Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: